ACVR2A and pulmonary arterial hypertension: Therapeutic use of ActRIIA-Fc (sotatercept) provides clinically meaningful improvement in patients with PAH, even in those receiving multiple background therapies (21), underscoring the strong pathogenic roles for activin receptor signaling in PAH progression.